lapatinib has been researched along with ch5164840 in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (ch5164840) | Trials (ch5164840) | Recent Studies (post-2010) (ch5164840) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 6 | 0 | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, Y; Fujii, T; Hada, K; Ishii, N; Kondoh, O; Mio, T; Miura, T; Nakanishi, Y; Nakano, K; Ono, N; Saitoh, R; Sakata, K; Sato, S; Suda, A; Tachibana, Y; Tsukuda, T; Yamazaki, T | 1 |
1 other study(ies) available for lapatinib and ch5164840
| Article | Year |
|---|---|
Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |